Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321526 | 0.84 | AAK1 (0.40) | KDM4EALDH1A1AAK1MAPTAKR1B1 | |
| SCHEMBL31167218 | 0.84 | ALDH1A1 (0.34) | KDM4EALDH1A1AAK1MAPT | |
| SCHEMBL29860504 | 0.84 | AAK1 (0.40) | KDM4EALDH1A1AAK1MAPTAKR1B1 | |
| SCHEMBL983915 | 0.80 | ALOX5 (0.44) | DPP4HMGCRPTPN1 | |
| SCHEMBL24502989 | 0.77 | PDE4A (0.33) | KDM4EALDH1A1MAPT | |
| SCHEMBL20607948 | 0.76 | HTR2A (0.31) | KDM4EALDH1A1 | |
| SCHEMBL26932098 | 0.74 | HTR2A (0.42) | KDM4EALDH1A1MAPT | |
| SCHEMBL8710167 | 0.73 | CCR6 (0.31) | CCR6HKDC1 | |
| SCHEMBL20607716 | 0.73 | PRKDC (0.54) | KDM4EALDH1A1MAPTBACE1 | |
| SCHEMBL31758608 | 0.73 | HTR2A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101959890-B | Pyrrolopyrimidine carboxamides | NYCOMED GMBH | 2013-10-30 | — | — | CN | disclosed |
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| CN-101959890-A | Pyrrolopyrimidine carboxamides | NYCOMED GMBH | 2011-01-26 | — | — | CN | disclosed |
| EP-2247594-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009106531-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | KDM4E 1035/4885ALDH1A1 924/4885DPP4 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.